HELIXBIND, INC.

Marlborough, MA · Founded 2012 · Medtech · Private

RaPID/LD, an ultra-sensitive molecular diagnostic test for direct detection of Borrelia bacteria in whole blood using proprietary binding technology

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · helixbind.com

Sector: Medtech
Headquarters: Marlborough, MA
Founded: 2012
Latest Form D: $2.9M, Oct 2017
Total capital: $48.1M

Federal grants: $43.6M; 39 awards · 2015–2026; Rank in peer group#1 of 112
Private capital raised: $4.5M; 2 Form D · last Oct 2017; 108 months since last filing
Federal contracts: None on recordNo federal contract awards found.
Granted patents: 10; 13 pending · first 2020; Rank in peer group#4 of 112

Capital timeline

Latest events

Jun 2026Federal grantHealth and Human S · Phase II · An automated culture-free system for the identification of bloodstream infections direct from blood$1M
Jun 2026Federal grantHealth and Human S · Phase II · Direct-from-specimen identification of pathogens common in endocarditis$987K
Jul 2025Federal grantHealth and Human S · Phase II · An automated culture-free system for the identification of bloodstream infections direct from blood$1M
Jun 2025Federal grantHealth and Human S · Phase II · Diagnostic tool for assessment and tracking of microbial load in bloodstream infections$996K
Dec 2024Federal grantHealth and Human S · Phase II · Direct-from-specimen identification of pathogens common in endocarditis$1M
Jul 2024Federal grantHealth and Human S · Phase II · Direct from blood identification of bloodstream infections in newborns$996K
Jul 2024Federal grantHealth and Human S · Phase II · Direct detection and identification of antimicrobial resistance genes in bloodstream infections$1M
Oct 2017Private capital raisedForm D · SEC · 2nd filing$2.9M
Feb 2014Private capital raisedForm D · SEC · 1st filing$1.6M

Show 32 earlier federal awards

Jul 2024Federal grantHealth and Human S · Phase II · An automated culture-free system for the identification of bloodstream infections direct from blood$1M
May 2024Federal grantHealth and Human S · Phase II · Diagnostic tool for assessment and tracking of microbial load in bloodstream infections$985K
Jan 2024Federal grantHealth and Human S · Phase II · Direct-from-specimen identification of pathogens common in endocarditis$1M
Aug 2023Federal grantHealth and Human S · Phase II · Direct detection and identification of antimicrobial resistance genes in bloodstream infections$1M
Jul 2023Federal grantHealth and Human S · Phase II · Direct from blood identification of bloodstream infections in newborns$991K
Jun 2023Federal grantHealth and Human S · Phase II · Diagnostic tool for assessment and tracking of microbial load in bloodstream infections$1.1M
Mar 2023Federal grantHealth and Human S · Phase II · An Integrated Device for Rapid Bacteremia Diagnosis Direct from Whole Blood$1M
Mar 2023Federal grantHealth and Human S · Phase II · Massively Multiplexed dsDNA Invasion Arrays$1M
Aug 2022Federal grantHealth and Human S · Phase II · Direct detection and identification of antimicrobial resistance genes in bloodstream infections$1.1M
Aug 2022Federal grantHealth and Human S · Phase II · Direct from blood identification of bloodstream infections in newborns$995K
May 2022Federal grantHealth and Human S · Phase II · Development of an automated IVD for the ultra-sensitive, direct, molecular detection of Borrelia for early Lyme Disease$981K
Apr 2022Federal grantHealth and Human S · Phase II · Massively Multiplexed dsDNA Invasion Arrays$1M
Mar 2022Federal grantHealth and Human S · Phase II · A Culture-Free Platform for Rapid Fungal Pathogen Identification$1M
Mar 2022Federal grantHealth and Human S · Phase II · An Integrated Device for Rapid Bacteremia Diagnosis Direct from Whole Blood$1M
May 2021Federal grantHealth and Human S · Phase II · Development of an automated IVD for the ultra-sensitive, direct, molecular detection of Borrelia for early Lyme Disease$992K
Apr 2021Federal grantHealth and Human S · Phase II · Massively Multiplexed dsDNA Invasion Arrays$1M
Mar 2021Federal grantHealth and Human S · Phase II · An Integrated Device for Rapid Bacteremia Diagnosis Direct from Whole Blood$1M
Mar 2021Federal grantHealth and Human S · Phase II · A Culture-Free Platform for Rapid Fungal Pathogen Identification$1M
Dec 2020Federal grantHealth and Human S · Phase II · An automated platform for direct-from-specimen identification of pathogens common in endocarditis$1M
Jun 2020Federal grantHealth and Human S · Phase II · Development of an automated IVD for the ultra-sensitive, direct, molecular detection of Borrelia for early Lyme Disease$3M
Apr 2020Federal grantHealth and Human S · Phase II · A Culture-Free Platform for Rapid Fungal Pathogen Identification$1M
Jan 2020Federal grantHealth and Human S · Phase II · An automated platform for direct-from-specimen identification of pathogens common in endocarditis$998K
Jan 2019Federal grantHealth and Human S · Phase II · An automated platform for direct-from-specimen identification of pathogens common in endocarditis$3M
Aug 2018Federal grantHealth and Human S · Phase II · A sample-to-answer diagnostic for neonatal bloodstream infections$997K
Jul 2018Federal grantHealth and Human S · Phase II · An Integrated Device for Rapid Bacteremia Diagnosis from Whole Blood$411K
Jan 2018Federal grantHealth and Human S · Phase I · Culture-free identification of pathogens common in endocarditis directly from patient specimens$300K
Sep 2017Federal grantHealth and Human S · Phase II · A sample-to-answer diagnostic for neonatal bloodstream infections$2M
Jun 2017Federal grantHealth and Human S · Phase II · An Integrated Device for Rapid Bacteremia Diagnosis from Whole Blood$984K
Jul 2016Federal grantHealth and Human S · Phase II · A Culture-Free Platform for Rapid Pathogen Identification$697K
Jul 2016Federal grantHealth and Human S · Phase II · An Integrated Device for Rapid Bacteremia Diagnosis from Whole Blood$2.4M
Sep 2015Federal grantHealth and Human S · Phase I · A sample-to-answer diagnostic for neonatal blood stream infections$225K
Aug 2015Federal grantHealth and Human S · Phase II · A Culture-Free Platform for Rapid Pathogen Identification$1.5M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Standing among 112 peers

Line = median

Medtech · Instrument

Federal grants#1 · top 1%
Granted patents#4 · top 4%
Linked publications#18 · top 16%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

Researcher links verified by same-company patents and grants

Alon SingerResearcherExecutive Officer, Director, PromoterLinked by 10 patents · $43.6M in grants as PI
Larry PearsonDirectorNamed in SEC Form D filings
Sheppard MollickDirectorNamed in SEC Form D filings

What it has protected

USPTO · 10 granted of 23

Jun 2, 2026GrantedMethods And Devices For Detecting And Identifying MicroorganismsUSPTOUS 12,644,158
Mar 31, 2026GrantedIntegrated Fluidic Devices And Related MethodsUSPTOUS 12,589,387
Jan 6, 2026GrantedMethods And Devices For Identifying Microbial InfectionsUSPTOUS 12,516,387

Show all 23 patent records

Methods And Devices For Detecting And Identifying MicroorganismsJun 2, 2026 · US 12,644,158Granted
Integrated Fluidic Devices And Related MethodsMar 31, 2026 · US 12,589,387Granted
Methods And Devices For Identifying Microbial InfectionsJan 6, 2026 · US 12,516,387Granted
Integrated Fluidic Devices And Related MethodsMay 7, 2024 · US 11,975,320Granted
Methods And Devices For Ultrasensitive Direct Detection Of MicroorganismsJan 25, 2024 · Application 18351061Pending
Methods And Devices For Identifying Microbial InfectionsDec 12, 2023 · US 11,840,721Granted
Methods And Devices For Ultrasensitive Direct Detection Of MicroorganismsAug 1, 2023 · US 11,713,330Granted
Reagent Carriers For Fluidic SystemsJun 8, 2023 · Application 18101870Pending
Reagent Carriers For Fluidic SystemsFeb 28, 2023 · US 11,590,507Granted
Methods And Devices For Detecting And Identifying MicroorganismsAug 16, 2022 · US 11,414,712Granted
Methods And Compositions For The Diagnosis Of Sepsis Using Gamma Peptide Nucleic AcidsJan 6, 2022 · Application 17370819Pending
Methods And Compositions For The Diagnosis Of Sepsis Using Gamma Peptide Nucleic AcidsAug 17, 2021 · US 11,091,814Granted
Integrated Fluidic Devices And Related MethodsAug 4, 2020 · US 10,730,041Granted
Methods And Devices For Depleting Eukaryotic DnaApplication 62051447Pending
Reagent Carriers For Fluidic SystemsApplication PCTUS2021019369Pending
Methods And Devices For Ultrasensitive Direct Detection Of MicroorganismsApplication PCTUS2020028109Pending
Reagent Carriers For Fluidic SystemsApplication 62981409Pending
Methods And Devices For Ultrasensitive Direct Detection Of MicroorganismsApplication 62834729Pending
Methods And Devices For Identifying Microbial InfectionsApplication PCTUS2018025681Pending
Methods And Devices For Identifying Microbial InfectionsApplication 62480953Pending
Integrated Fluidic Devices And Related MethodsApplication PCTUS2017022280Pending
Fluidic Devices And Related MethodsApplication 62308031Pending
Methods And Devices For Detecting And Identifying MicroorganismsApplication PCTUS2015050741Pending

Recent research by its founders

Technical advances in laboratory diagnosis of bloodstream infection20253 cites
Culture-independent identification of bloodstream infections from whole blood: prospective evaluation in specimens of known infection status202415 cites
Are local species prioritization lists sufficient for protecting endangered plants? Israeli red list as a test case20241 cites

Vixiar Medical, IncSimilar federal contract value in Medtech · null in contracts
POWELL MANSFIELD, INC.Similar federal contract value in Medtech · null in contracts
MELLITUS, LLCSimilar federal contract value in Medtech · null in contracts
HARMONUS, INC.Similar federal contract value in Medtech · null in contracts
EARLY IS GOOD INC.Similar federal contract value in Medtech · null in contracts
REVBIO, INC.Similar federal contract value in Medtech · null in contracts

Regulatory activity · Medtech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.